Chronic Gout Market By Product Type (Urate-Lowering Therapies, Anti-Inflammatory Therapies, Combination and Supportive Therapies), Application (Long-Term Urate Reduction, Acute Gout Flare Management, Flare Prevention, Chronic Tophaceous Gout, Refractory and Uncontrolled Gout), End User (Hospitals, Rheumatology Clinics, Primary Care Clinics, Specialty Infusion Centers, Retail and Hospital Pharmacies, Homecare Settings), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Chronic Gout Market: Treat-to-Target Care Turns an Adherence Gap into a Commercial Battleground

The Global Chronic Gout Market was valued at USD 3.35 billion in 2025 and is projected to reach USD 5.53 billion by 2032, expanding at a CAGR of 7.6% during 2026–2032, according to internal projections by Strategic Market Research.

 

The chronic gout market is driven by patients whose uric acid remains uncontrolled for long periods. These patients may experience repeated flares, persistent joint pain, visible tophi, stiffness, mobility loss, kidney-related treatment limits, or joint damage. Their care extends beyond occasional pain relief and often requires lifelong urate-lowering medicines, regular blood tests, preventive anti-inflammatory treatment, specialist consultations, and, in severe cases, infusion therapy.

 

Global gout prevalence reached approximately 55.8 million cases in 2020, representing a 22.5% increase from 1990. The number of cases is projected to rise by 72.6% to 95.8 million by 2050. Men had 3.26 times the age-standardized prevalence of women in 2020. Population growth and ageing are expected to account for much of the future increase, creating a larger pool of patients who may progress to chronic or uncontrolled disease when uric acid is not consistently reduced.

 

Chronic gout develops gradually as urate crystals continue to build up in joints and surrounding tissues. Long periods without pain can give patients the impression that the condition has resolved, even though crystal deposition may continue. When preventive treatment is delayed or stopped, occasional attacks can progress into more frequent flares, persistent discomfort, tophi, joint stiffness, and structural damage. This progression increases demand for daily medicines, serum urate testing, imaging, specialist care, adherence programs, and advanced treatment for patients who no longer respond adequately to standard tablets.

 

Clinical guidelines now place greater emphasis on controlling uric acid rather than treating each flare as a separate event. The American College of Rheumatology recommends allopurinol as the preferred first-line urate-lowering therapy, including for many patients with chronic kidney disease, with a serum urate target below 6 mg/dL. NICE advises clinicians to consider a target below 5 mg/dL for patients with tophi, chronic gouty arthritis, or continued frequent flares. Colchicine, an NSAID, or another anti-inflammatory medicine may be prescribed when urate-lowering therapy begins because changes in crystal deposits can temporarily trigger additional attacks.

 

The Treatable Disease with a Persistent Treatment Gap

The main gap in the chronic gout market is not a shortage of established medicines. It is the low number of patients who start treatment, remain on it, receive appropriate dose adjustments, and reach the recommended uric acid target.

A nationally representative study found that only 28.9% of US adults with gout were using urate-lowering therapy. Even among patients taking these medicines, 49% still had serum urate levels at or above 6 mg/dL. The control gap was wider among medically complex patients. Approximately 66% of people with gout and stage 2–5 chronic kidney disease or kidney stones remained above the recommended level. These findings show that writing a prescription does not guarantee disease control. Patients also need follow-up testing, dose escalation, refill support, and alternative treatment when the first medicine is insufficient.

The burden of uncontrolled disease is also visible in the US Veterans Health Administration. A 2025 analysis identified 331,664 patients with gout between 2016 and 2022, and 42% met the study criteria for uncontrolled gout. These patients used more rheumatology, nephrology, podiatry, emergency-department, and hospital services than patients whose gout was controlled. Although the veteran population differs from the wider US population, the findings show how poor uric acid control can turn a condition usually managed in primary care into a more costly and treatment-intensive disease. 

England faces a similar treatment gap. NICE estimated that approximately 1.4 million people, or 2.49% of the population, had gout. Only around one-third received appropriate medicines, and only one-third of those treated used therapy effectively enough to reach the uric acid target. Among approximately 520,000 people receiving urate-lowering therapy in the NICE resource model, 78% remained above 360 μmol/L under current practice. Better diagnosis, dose adjustment, testing, and treatment persistence could therefore expand the treated market without relying only on growth in the number of newly diagnosed patients. 

 

Adherence Determines Whether Prescription Volume Becomes Disease Control

Urate-lowering therapy must usually be taken every day, including during periods when the patient has no pain. This creates one of the most important challenges in the chronic gout market. Patients may stop treatment early, take tablets irregularly, or continue on a dose that is too low to achieve the required uric acid level.

A meta-analysis of 22 studies covering 137,699 patients found an overall urate-lowering therapy adherence rate of 47%. The result varied according to how adherence was measured. Studies using prescription claims reported pooled adherence of 42%, compared with 66% in self-reported surveys and 63% in patient interviews. The difference suggests that patients may believe they are following treatment more consistently than their refill records indicate. 

Treatment initiation can also affect adherence. Urate-lowering medicines may temporarily increase flare frequency as existing crystal deposits begin to change. Patients who are not given preventive anti-inflammatory treatment or clear counselling may assume that the new medicine is making their condition worse and stop taking it. Long periods between attacks create another problem because patients may discontinue daily treatment once the pain disappears, even though their uric acid level remains high. 

Structured follow-up can improve long-term results. In the five-year NOR-Gout study, 33.3% of patients in the lowest adherence group reported a flare during the previous year, compared with 9.5% in the highest adherence group. Serum urate target achievement increased from 45.2% among the least-adherent patients to 87.5% among the most-adherent patients. These results support demand for nurse-led dose adjustment, pharmacist follow-up, refill reminders, laboratory coordination, and patient-support programs that help people remain on treatment. 

 

Oral Generics Control Treatment Volume

Allopurinol remains the leading urate-lowering medicine because it is inexpensive, widely available, familiar to clinicians, and recommended as the preferred first-line treatment. It is used across a broad patient population, including many people with chronic kidney disease when started carefully and adjusted according to serum urate response.

Febuxostat provides another option for patients who do not respond adequately to allopurinol, cannot tolerate it, or have a clinical reason not to use it. Its US label, however, carries a boxed warning concerning cardiovascular death in patients with established cardiovascular disease. US febuxostat use declined after the safety warning, while allopurinol retained its dominant position. This has left the oral market heavily concentrated around a low-cost generic medicine, while preserving demand for safer or more effective options for patients who remain uncontrolled.

NICE estimated that allopurinol accounted for 86% of patients receiving urate-lowering therapy in England, compared with 14% for febuxostat. Growth in the oral segment therefore depends less on premium pricing and more on identifying untreated patients, increasing suitable doses, maintaining refills, and checking whether serum urate falls to target. Probenecid and other uricosuric medicines serve a smaller group because their use can be limited by kidney function, kidney-stone risk, and interactions with other medicines. 

 

Refractory Gout Concentrates Premium Revenue

A smaller group of patients continues to experience severe gout despite standard oral treatment. These patients may have persistent tophi, repeated attacks, joint damage, or uric acid levels that remain above target. Although the eligible population is smaller, treatment costs per patient are considerably higher.

Pegloticase is used in adults with chronic gout that has not responded to conventional therapy. It is administered intravenously in a healthcare setting because patients require monitoring for infusion reactions and anaphylaxis. The labelled regimen also includes co-administration with methotrexate, adding further medication and monitoring requirements. The treatment pathway involves specialist consultations, laboratory testing, infusion appointments, and payer authorization, making refractory gout the highest-value part of the market. 

Amgen reported that KRYSTEXXA generated USD 1.3 billion in sales during 2025, representing an increase of 13%. This figure does not represent the entire chronic gout market because KRYSTEXXA is intended for a narrowly defined uncontrolled population. It does, however, show the commercial value created when patients progress beyond standard oral medicines and require specialist treatment. Competition is therefore focused on improving advanced urate-lowering therapy and identifying patients before extensive joint damage develops. 

 

Flare Treatment Retains Volume but Cannot Remove Urate Burden

NSAIDs, colchicine, and corticosteroids remain widely used during gout attacks because they reduce pain, swelling, and inflammation. NICE modelling estimated that NSAIDs accounted for 69% of flare treatment in England, followed by colchicine at 30% and corticosteroids at 1%.

These medicines generate substantial prescription volume, but they do not lower uric acid or dissolve existing crystal deposits. Patients who rely mainly on flare medicines may experience temporary relief while the underlying disease continues to progress. This distinction is important to the chronic gout market because repeated rescue treatment does not replace daily urate-lowering therapy. 

Frequent anti-inflammatory use can also become difficult in patients with kidney disease, gastrointestinal risk, cardiovascular disease, hypertension, diabetes, or several concurrent medicines. These comorbidities are common among people with chronic gout and may reduce the suitability of NSAIDs or other flare treatments. Long-term uric acid control can lower dependence on repeated rescue medicines, although preventive colchicine or an NSAID may still be required during the first months of urate-lowering therapy.

 

Treat-to-Target Care Shifts Spending Toward Monitoring

Treat-to-target care increases spending on regular prescriptions, serum urate testing, consultations, and dose adjustments. It can also reduce the number of attacks and the need for unscheduled medical care.

NICE estimated that implementing its gout recommendations would increase prescribing expenditure in England by £3.2 million in 2022/23, rising to £10.2 million in 2026/27. These figures excluded the additional cost of consultations and monitoring. The model assumed that patients without urate-lowering therapy experienced 4.2 flares per year, compared with 1.5 flares among patients receiving treat-to-target care.

For an average general practice serving 10,000 people, full implementation was expected to require 80 additional monitoring appointments while avoiding 57 consultations for gout flares each year. Spending therefore moves away from repeated rescue care and toward planned disease management.

This model creates demand for laboratory services, nurse-led reviews, pharmacist involvement, digital reminders, and primary-care follow-up. However, simply increasing allopurinol prescriptions will not deliver the full benefit. Treatment must be followed by testing and dose adjustment until the patient reaches the recommended uric acid level.

 

Pipeline Competition Targets the Gap Before Infusion

The main development opportunity lies between low-cost first-line tablets and high-cost infusion therapy. Companies are targeting patients who remain above the uric acid goal despite standard oral treatment but have not yet moved to intravenous uricase therapy.

In February 2026, Sobi completed its acquisition of Arthrosi Therapeutics. The transaction included USD 950 million upfront and up to USD 550 million in potential milestone payments. The acquisition added pozdeutinurad, a once-daily oral URAT1 inhibitor being developed for progressive and tophaceous gout that remains inadequately controlled with existing urate-lowering medicines. The size of the transaction reflects industry interest in an oral treatment that could be used before patients require infusion therapy.  

In the Phase 3 REDUCE 2 study, 69.2% of patients receiving 75 mg pozdeutinurad and 56.6% receiving 50 mg reached serum urate below 6 mg/dL at month six. Only 8.1% of patients receiving placebo reached the same target. REDUCE 1 results are expected in the fourth quarter of 2026. Approval and commercial adoption will depend on safety findings, regulatory review, payer coverage, and whether the medicine provides a clear advantage for patients who remain uncontrolled despite properly adjusted generic treatment. 

Sobi is also developing nanoencapsulated sirolimus plus pegadricase for uncontrolled gout requiring intensive urate reduction. In 2026, the FDA issued a Complete Response Letter related to manufacturing controls and findings involving a contract manufacturer. Sobi stated that the agency did not identify clinical efficacy or safety problems affecting approvability. The delay shows that manufacturing quality and regulatory execution can influence market entry even when a therapy has produced acceptable clinical results. 

 

North America Leads Value While Public Systems Drive Scale

North America leads the chronic gout market in commercial value because of its large diagnosed population, specialist infusion network, biologic reimbursement, and the established KRYSTEXXA franchise. Low US urate-lowering therapy use and poor target achievement also leave a substantial patient population available for better adherence programs, dose optimization, and newer oral therapies.

The 28.9% ULT utilization rate, the high proportion of treated patients who remain above target, and the 42% uncontrolled gout rate reported in the veteran population show that unmet need is not limited to undiagnosed patients. A large share of market potential comes from people already known to the healthcare system but not adequately controlled.

European public healthcare systems offer volume opportunities through broader implementation of guideline-based treatment. Pricing is more tightly controlled, and new products must demonstrate that higher treatment spending can reduce flares, consultations, and other medical costs. NICE’s analysis shows that treat-to-target care requires greater near-term spending on medicines and monitoring while reducing the frequency of attacks.

Asia-Pacific has a growing gout population associated with ageing, obesity, kidney disease, and metabolic conditions. Wider access to generic medicines can increase patient volumes, although public pricing controls and differences in specialist access may keep average revenue per patient below US levels.

 

Chronic Gout Market Outlook

A reliable standalone global market size or CAGR for chronic gout cannot be calculated from public evidence because available datasets often combine acute gout, chronic gouty arthritis, tophaceous gout, progressive gout, refractory gout, and uncontrolled gout. Market evaluation should therefore separate three revenue areas: high-volume flare medicines, recurring oral urate-lowering therapy with monitoring, and high-value specialist treatment for refractory disease.

Future market growth will depend on how many patients move from occasional flare treatment to sustained uric acid control. Untreated patients need to begin urate-lowering therapy, treated patients need to remain adherent, and doses must be adjusted until serum urate reaches target. Patients who remain uncontrolled will require alternative oral medicines, combination treatment, or biologic therapy.

Allopurinol is expected to remain the volume leader because of its low cost and first-line position. Premium revenue will remain concentrated among patients with persistent tophi, repeated flares, intolerance to standard medicines, or failure of conventional treatment. KRYSTEXXA’s USD 1.3 billion in 2025 sales and Sobi’s investment in late-stage gout therapies show that the strongest commercial opportunity lies in closing the gap between inexpensive oral treatment and advanced infusion care. 

 

Chronic Gout Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.35 Billion
Revenue Forecast in 2032	USD 5.53 Billion
Overall Growth Rate	CAGR of 7.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Urate-Lowering Therapies, Anti-Inflammatory Therapies, Combination and Supportive Therapies
By Application	Long-Term Urate Reduction, Acute Gout Flare Management, Flare Prevention, Chronic Tophaceous Gout, Refractory and Uncontrolled Gout
By End User	Hospitals, Rheumatology Clinics, Primary Care Clinics, Specialty Infusion Centers, Retail and Hospital Pharmacies, Homecare Settings
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising gout prevalence, increasing burden of uncontrolled uric acid levels, growing adoption of treat-to-target care, demand for long-term urate-lowering therapy, rising serum urate monitoring, expansion of specialist rheumatology care, and development of advanced oral and biologic therapies for refractory gout
Customization Option	Available upon request